ECSP034451A - Composicion de eletriptan en forma de particulas - Google Patents

Composicion de eletriptan en forma de particulas

Info

Publication number
ECSP034451A
ECSP034451A EC2003004451A ECSP034451A ECSP034451A EC SP034451 A ECSP034451 A EC SP034451A EC 2003004451 A EC2003004451 A EC 2003004451A EC SP034451 A ECSP034451 A EC SP034451A EC SP034451 A ECSP034451 A EC SP034451A
Authority
EC
Ecuador
Prior art keywords
composition
eletriptan
pharmaceutical composition
core
particles
Prior art date
Application number
EC2003004451A
Other languages
English (en)
Inventor
Ross James Macrae
Manaud Pierre Raspide
Mathias Walther
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP034451A publication Critical patent/ECSP034451A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electroluminescent Light Sources (AREA)
  • Luminescent Compositions (AREA)

Abstract

Esta invención proporciona una composición farmacéutica en forma de partículas, adecuada para la administración por vía oral que incluye un núcleo que contiene eletriptan o una sal farmacéuticamente aceptable del mismo, estando revestido el núcleo con un revestimiento insoluble en agua y permeable que incluye uno o más copolímeros acrílicos que contienen grupos de metecrilato de trimetilamonioetilo, y siendo dicha composición capaz de conseguir un curso sigmoideo de liberación controlada del fármaco. Esta composición farmacéutica es particularmente útil en la prevención de la recurrencia de la migraña.
EC2003004451A 2000-08-02 2003-01-24 Composicion de eletriptan en forma de particulas ECSP034451A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0018968.8A GB0018968D0 (en) 2000-08-02 2000-08-02 Particulate composition

Publications (1)

Publication Number Publication Date
ECSP034451A true ECSP034451A (es) 2003-03-10

Family

ID=9896843

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004451A ECSP034451A (es) 2000-08-02 2003-01-24 Composicion de eletriptan en forma de particulas

Country Status (38)

Country Link
US (1) US20020034545A1 (es)
EP (1) EP1365748B1 (es)
JP (1) JP2004505034A (es)
KR (1) KR20030024820A (es)
CN (1) CN1630511A (es)
AP (1) AP2001002233A0 (es)
AR (1) AR030099A1 (es)
AT (1) ATE308978T1 (es)
AU (1) AU2001270932A1 (es)
BG (1) BG107361A (es)
BR (1) BR0112839A (es)
CA (1) CA2417887C (es)
CZ (1) CZ2003241A3 (es)
DE (1) DE60114887T2 (es)
EA (1) EA200300110A1 (es)
EC (1) ECSP034451A (es)
EE (1) EE200300051A (es)
ES (1) ES2250429T3 (es)
GB (1) GB0018968D0 (es)
GT (1) GT200100149A (es)
HR (1) HRP20030036A2 (es)
HU (1) HUP0301453A2 (es)
IL (1) IL153494A0 (es)
IS (1) IS6649A (es)
MA (1) MA26934A1 (es)
MX (1) MXPA03000999A (es)
NO (1) NO20030498D0 (es)
NZ (1) NZ522976A (es)
OA (1) OA12348A (es)
PA (1) PA8523101A1 (es)
PE (1) PE20020385A1 (es)
PL (1) PL359847A1 (es)
SK (1) SK1082003A3 (es)
SV (1) SV2002000574A (es)
TN (1) TNSN01115A1 (es)
UY (1) UY26861A1 (es)
WO (1) WO2002009675A1 (es)
ZA (1) ZA200300868B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
WO2004054518A1 (en) * 2002-12-16 2004-07-01 Chx Technologies, Inc. Temporary, pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing
EP1615635A1 (en) * 2003-04-11 2006-01-18 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
WO2005120456A2 (en) * 2004-06-09 2005-12-22 Pfizer Limited Formulation of eletriptan
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan
JPWO2006080481A1 (ja) * 2005-01-31 2008-06-19 杏林製薬株式会社 マルチプルユニット型経口徐放性製剤及びその製造方法
WO2007016948A1 (de) 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Orales präparat mit kontrollierter freisetzung
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
US7722898B2 (en) 2006-04-26 2010-05-25 Supernus Pharmaceuticals, Inc. Modified-release preparations containing oxcarbazepine and derivatives thereof
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
WO2009015336A2 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
ES2671036T3 (es) 2009-11-16 2018-06-04 Evonik Röhm Gmbh Un proceso de conversión de un copolímero de (met)acrilato sólido en una forma dispersa por medio de un agente dispersante
WO2016040358A1 (en) * 2014-09-09 2016-03-17 Charleston Laboratories, Inc. Pharmaceutical compositions
GB201716716D0 (en) * 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release

Also Published As

Publication number Publication date
HUP0301453A2 (hu) 2003-08-28
AR030099A1 (es) 2003-08-13
BR0112839A (pt) 2003-06-24
TNSN01115A1 (fr) 2005-11-10
PL359847A1 (pl) 2004-09-06
BG107361A (bg) 2003-06-30
NZ522976A (en) 2004-11-26
ES2250429T3 (es) 2006-04-16
CZ2003241A3 (cs) 2004-02-18
PA8523101A1 (es) 2002-08-26
CA2417887A1 (en) 2002-02-07
HRP20030036A2 (en) 2003-04-30
MA26934A1 (fr) 2004-12-20
PE20020385A1 (es) 2002-05-11
EE200300051A (et) 2004-10-15
IL153494A0 (en) 2003-07-06
JP2004505034A (ja) 2004-02-19
KR20030024820A (ko) 2003-03-26
NO20030498L (no) 2003-01-31
NO20030498D0 (no) 2003-01-31
IS6649A (is) 2002-12-05
AP2001002233A0 (en) 2001-09-30
GB0018968D0 (en) 2000-09-20
OA12348A (en) 2004-03-19
MXPA03000999A (es) 2003-06-09
WO2002009675A1 (en) 2002-02-07
DE60114887T2 (de) 2006-07-20
CN1630511A (zh) 2005-06-22
GT200100149A (es) 2002-06-25
EP1365748B1 (en) 2005-11-09
EA200300110A1 (ru) 2003-06-26
AU2001270932A1 (en) 2002-02-13
ATE308978T1 (de) 2005-11-15
SV2002000574A (es) 2002-12-02
SK1082003A3 (en) 2004-09-08
US20020034545A1 (en) 2002-03-21
WO2002009675A9 (en) 2003-09-18
DE60114887D1 (de) 2005-12-15
EP1365748A2 (en) 2003-12-03
ZA200300868B (en) 2004-04-16
CA2417887C (en) 2006-11-14
UY26861A1 (es) 2002-02-28

Similar Documents

Publication Publication Date Title
ECSP034451A (es) Composicion de eletriptan en forma de particulas
CY1106072T1 (el) Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος
ES2524556T3 (es) Composiciones farmacéuticas
DOP2001000229A (es) Forma de dosificación de fármaco activada por hidrogel
ATE391496T1 (de) Geschmacksmaskierte pharmazeutische formulierungen
CO5261492A1 (es) Formas de dosificacion de liberacion controlada que comprenden zolpidem o sales del mismo
IL173078A0 (en) Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form
DE60334378D1 (de) Zusammensetzung zur kontrollierten wirkstoffabgabe
ATE266390T1 (de) Stossweise freisetzende arzneiabgabesysteme
ES2185816T3 (es) Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
CO5190681A1 (es) Formas de dosificacion farmaceutica para la liberacion controlada que producen al menos un impulso ciclico
PT939626E (pt) Forma galenica de libertacao prolongada de milnaciprano
PE20191048A1 (es) Formas de dosificacion farmaceutica
ATE477795T1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
MX9701465A (es) Formulacion de acetaminofeno, de liberacion sostenida.
CO5611097A2 (es) Tableta farmaceutica
CO5690538A2 (es) Formulaciones de multiples particulas de pantoprazol
DK1345595T3 (da) Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse
DK1169032T3 (da) Ketoprofen-mikrogranuler, fremgangsmåde til fremstilling deraf og farmaceutiske præparater
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
DE69927374D1 (de) Entzündungshemmende pharmazeutische formulierungen
ATE367153T1 (de) Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
ECSP066318A (es) Composición para la liberación de una base debil por un periodo extendido de tiempo
CR6858A (es) Composiciones de eletriptan en forma de particulas que muestra el curso sigmoideo de liberacion controlada